Reckitt Benckiser Proposes Sale of E45 Brands to Karo Pharma
24 Dicembre 2021 - 8:46AM
Dow Jones News
By Sabela Ojea
Reckitt Benckiser Group PLC said Friday it is proposing to sell
its E45 skincare brand and related sub-brands to Karo Pharma AB for
an implied enterprise value of 200 million pounds ($268.2
million).
The consumer-goods company--which houses Dettol, Harpic and
Durex among its brands--said E45 generated a combined net revenue
of GBP43 million for the year ended Dec. 31, 2020.
"The proposed sale, if completed, would be another step forward
in Reckitt's plan to actively manage its portfolio for higher
growth," the London-listed company said.
The transaction is expected to be completed in the first quarter
of 2022, it said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
December 24, 2021 02:31 ET (07:31 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Grafico Azioni Reckitt Benckiser (LSE:RKT)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Reckitt Benckiser (LSE:RKT)
Storico
Da Apr 2023 a Apr 2024
